Young biotech Dropshot Therapeutics has hooked in Etherna Immunotherapies with an RNA pact that could net up to $950 million.

Angelini Ventures has co-led a €20 million Series A financing round in Neumirna Therapeutics. The financing, also led by ...

Oppenheimer analyst Andreas Argyrides initiated coverage of ProQR Therapeutics (PRQR) with an Outperform rating and $15 price target The firm ...

Novel paradigm for therapeutics based on RNA splicing modulationLead program in Huntington’s diseaseDenmark – Odense – 07/01/2025 – Inverna ...

As part of the agreement, Sanofi will provide Alloy with upfront license fees and near-term preclinical milestone payments up ...

Alloy Therapeutics Inc. ("Alloy"), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug ...

City Therapeutics Announces Strategic Collaboration with Bausch + Lomb to Develop a Novel RNAi-Based Treatment for Geographic Atrophy ...

NV ("etherna"), a technology platform leader pioneering mRNA and lipid-based nanoparticle (LNP) technologies, announces a ...

The primary objective of this initial clinical trial is to evaluate safety and immune responses of three different dose levels and two different vaccination schedules of ARCT-2304 vaccine. Immune ...

City Therapeutics appoints CEO Andy Orth, with 25 years' corporate and commercial strategy expertise; Dr. John Maraganore ...

Vietnam RNAi Therapeutics Market Key Takeaways: The Vietnam RNAi Therapeutics market is undergoing robust growth, fueled by factors such as advancements in RNA interference (RNAi) technology, a ...